Study reveals possible link between IBD therapy and s... ( San Diego CA (October 26 2009) Fin...)

Study reveals possible link between IBD therapy and skin cancer

Date:10/29/2009

San Diego, CA (October 26, 2009) Findings from a new retrospective cohort study presented at the American College of Gastroenterology's 74th Annual Scientific meeting in San Diego indicate that patients with Inflammatory Bowel Disease (IBD), especially those receiving the thiopurine class of medications to treat IBD, may be at risk for developing non-melanoma skin cancer (NMSC).

Dr. Millie Long, of the University of North Carolina, Chapel Hill, and her colleagues examined the records of 26,403 patients with Crohn's disease and 26,974 patients with ulcerative colitis, dating from 1996 through 2005. The researchers investigated whether IBD could be associated with a higher risk of NMSC and whether the risk of NMSC increased as a result of immunosuppressive and biologic medications. Each IBD patient in the cohort study was matched according to age, gender and region of the country with three randomly selected control patient records who did not have Crohn's disease or ulcerative colitis. In addition, in a nested case-control study, 387 patients with Crohn's disease and NMSC and 355 patients with ulcerative colitis and NMSC were matched on age, gender and region of the country with four random control patients with Crohn's disease or ulcerative colitis who did not have NMSC to evaluate the impact of immunosuppressive and biologic medications on NMSC risk. According to the study findings, the incidence rate ratio (IRR) of NMSC was higher in patients with IBD compared to their matched controls (IRR: 1.64). In addition, recent use of any immunosuppressive medication (within 90 days) was associated with greater risk of NMSC (adjusted Odds Ratio (OR) 3.28), as was recent use of the thiopurine class of immunosuppressive medications (adjusted OR 3.56) and recent use of biologic medications in patients with Crohn's disease (adjusted OR 2.07).

Persistent use of any immunosuppressive medication (>365 days) was strongly associated with NMSC (adjust
'/>"/>

Contact: Jennifer Burke Labriola
burkepr@gmail.com
203-405-1479
American College of Gastroenterology
Source:Eurekalert

1

GOOD

Page: 1 2
Related medicine news :

1. New EPA Rodent Study Finds No Low-Dose BPA Effects on Reproductive Function or Behavior
2. U-M study uncovers key to how triggering event in cancer occurs
3. Finding Ways for Disabled People to Participate in Research is Goal of Case Western Reserve University Nursing School Study
4. Pitt study shows linkage between teen girls weight and sexual behavior
5. Diet, Exercise Thwart Diabetes: Study
6. Beaumont, U-M Open Study of Drug for Advanced Breast Cancer
7. Let Kids Sleep Late on Weekends to Fight Fat: Study
8. NeoVista Presents Interim Study Results of Novel Therapy for the Treatment of Neovascular Age-Related Macular Degeneration
9. Old, New Pap Methods Equally Good, Dutch Study Finds
10. Stanford study recommends change in treating pulmonary embolisms
11. Deadly stomach infection rising in community settings, Mayo Clinic study finds

Post Your Comments:

(Date:6/19/2013)... Quapaw, OK (PRWEB) June 19, 2013 ... of Companies, including RWI Benefits, LLC, Native Care ... The National Association of Health Underwriters’ (NAHU) new ... Affordable Care Act (PPACA). This continuing education course ... states, and Roberson will receive eleven education credits ...

(Date:6/19/2013)... According to a June 17, 2013 Allure ... is not uncommon for a person to suffer from a ... is likely to forget to reapply sunscreen properly and end ... and itchy. When this occurs, it is essential to act ... people do not realize that milk contains proteins, fats, and ...

(Date:6/19/2013)... In a major international study led by researchers at ... targeted therapy ibrutinib continues to show remarkable promise for ... (MCL). , The most recent interim findings of the ... New England Journal of Medicine . Previous interim ... American Society of Hematology Annual Meeting and Exposition. ...

(Date:6/19/2013)... Pa. (June 19, 2013) The results of three ... of Neurosurgery , official journal of the ... published by Lippincott Williams & Wilkins , a ... study indicates that continuous "machine learning" using artificial neural ... in patients with advanced brain cancers. Another study in ...

(Date:6/19/2013)... reveals significant disparities between minority and white clients ... programs. Moreover, these disparities vary widely from state ... for most states there,s something amiss," says Stephan ... "There are strong racial and ethnic disparities for ... treatment programs successfully, and those disparities are something ...

Breaking Medicine News(10 mins):Health News:RWI Benefits, LLC Becomes PPACA Certified 2 Health News:Skin Care – How to treat Sunburn 2 Health News:Ibrutinib continues strong showing against mantle cell lymphoma 2 Health News:Neurosurgery publishes findings of 3 important studies in June issue 2 Health News:Neurosurgery publishes findings of 3 important studies in June issue 3 Health News:States vary widely on success rates for minorities in drug treatment programs 2 Health News:States vary widely on success rates for minorities in drug treatment programs 3

[0] RWI Benefits, LLC Becomes PPACA Certified [0] Skin Care – How to treat Sunburn [0] Ibrutinib continues strong showing against mantle cell lymphoma [0] Neurosurgery publishes findings of 3 important studies in June issue [0] States vary widely on success rates for minorities in drug treatment programs

... Dec. 1 Acuo Technologies(R), developers,of high-performance software ... services, today announced the contracting with Rush,University ... new vendor neutral archiving,solution which becomes the basis ... archiving solution is based on the Acuo Technologies ...

... In recognition of World AIDS Day, Charlotte Bobcats, Emeka Okafor, will ... One Million African Lives Initiative (OMALI), a program of the Safe ... is to save one million lives in Africa by 2011 by ... , , OMALI will be ...

... TOMS Shoes, the philanthropic,footwear company, has launched a ... and Give More this holiday season. For 30,days, from ... to help give 30,000 pairs of shoes to children ... preventable by wearing shoes. By,purchasing a pair of shoes ...

... , , ANN ARBOR, ... pajamas or a video game are all quick and easy gifts to ... not give something more healthy and beneficial to a loved one? Why ... Staying healthy around the holidays can be challenging, and this ...

... Dec. 1 TorreyPines Therapeutics, Inc.,(Nasdaq: ... administration of NGX426, an,AMPA/kainate-type glutamate receptor antagonist, ... hyperalgesia (abnormally increased,pain state) and allodynia (pain ... compared to placebo following intradermal injections of ...

... Horvath, D.V.M., as Vice President of Preclinical Sciences and ... , CAMBRIDGE, Mass., Dec. ... Mass.-based executive team with the appointment of Jeffrey T. ... announced the additions of Christopher Horvath, D.V.M., as vice ...

Cached Medicine News:Health News:Acuo Technologies Announces Vendor Neutral Archiving Contract With Rush University Medical Center 2 Health News:Acuo Technologies Announces Vendor Neutral Archiving Contract With Rush University Medical Center 3 Health News:In Recognition of WORLD AIDS DAY, Charlotte Bobcats' Power Forward, Emeka Okafor, Launches Mobile Texting Campaign in Support of the One Million African Lives Initiative 2 Health News:TOMS Shoes Embarks on a Holiday Mission: Give 30,000 Pairs in 30 Days! 2 Health News:Giving the Gift of Health This Holiday Season 2 Health News:Giving the Gift of Health This Holiday Season 3 Health News:Giving the Gift of Health This Holiday Season 4 Health News:TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects 2 Health News:TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects 3 Health News:TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects 4 Health News:TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects 5 Health News:Taligen Therapeutics Advances Corporate Growth Plan with Appointment of Jeffrey T. Walsh as Chief Business Officer 2 Health News:Taligen Therapeutics Advances Corporate Growth Plan with Appointment of Jeffrey T. Walsh as Chief Business Officer 3

Acuo Technologies Announces Vendor Neutral Archiving Contract With Rush University Medical Center In Recognition of WORLD AIDS DAY, Charlotte Bobcats' Power Forward, Emeka Okafor, Launches Mobile Texting Campaign in Support of the One Million African Lives Initiative TOMS Shoes Embarks on a Holiday Mission: Give 30,000 Pairs in 30 Days!Giving the Gift of Health This Holiday Season TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects Taligen Therapeutics Advances Corporate Growth Plan with Appointment of Jeffrey T. Walsh as Chief Business Officer

(Date:6/19/2013)... BURLINGTON, Mass. , June 19, 2013 /PRNewswire/ ... and advisory firms for pharmaceutical and healthcare issues, ... the majority of surveyed U.S. and European rheumatologists ... of the attributes that most influences their prescribing ... U.S. and European rheumatologists, respectively, rank the percentage ...

(Date:6/19/2013)... , June 19, 2013 BD Biosciences, a segment ... ), a leading global medical technology company, today announced the ... the latest in its line of high-performance research flow cytometers. ... high-performance multicolor analysis with the most compact footprint in its ... and a height of 30" (76.2 cm). Recognizing that space ...

(Date:6/19/2013)... PRINCETON, N.J. , June 19, 2013 ... Belrose Pharma, a new specialty pharmaceutical company ... generation of innovative injectable and sustained release ... high unmet medical needs, today announced the ... (Customized Linker Technology®) platform and associated product ...

Breaking Medicine Technology:U.S. and European Rheumatologists Agree That a Therapy's Induction of Remission is One of the Attributes That Most Influences Their Prescribing Decisions in Rheumatoid Arthritis 2 New BD Biosciences Flow Cytometry Cell Analyzer Enables Complex Multicolor Experiments in Disease Research 2 Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 2 Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 3 Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 4

[0] U.S. and European Rheumatologists Agree That a Therapy's Induction of Remission is One of the Attributes That Most Influences Their Prescribing Decisions in Rheumatoid Arthritis [0] New BD Biosciences Flow Cytometry Cell Analyzer Enables Complex Multicolor Experiments in Disease Research [0] Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies

... YORK, Oct. 24, 2011 Reportlinker.com ... report is available in its catalogue: ... to 2017 - Glaucoma and Cataract ... Ophthalmic Surgery to Drive the Ophthalmic ...

... 2011 Phreesia, the patient check-in company, is committed ... practices nationwide with its electronic self-service check-in solution. One ... for practices is by automating the eligibility and benefits ... accurate billing by confirming coverage prior to the exam. ...

Ophthalmic Devices Market to 2017 - Glaucoma and Cataract Surgery Devices, Minimally Invasive Procedures in Ophthalmic Surgery to Drive the Ophthalmic Surgery Market Phreesia Continues to Enhance its Market-Leading Eligibility and Benefits Verification Process for Medical Practices

... to provide excellent protection and ease of ... being closer to an adhesive in molecular ... CoEase to maintain viscosity at high shear ... worlds for superb performance during capsulorhexis, phaco, ...

... viscosurgical device is a cohesive ... high molecular weight, high pseudoplasticity, ... provides excellent space maintenance, facilitates ... removed. It is available in ...

... VISUCAM DigitalCameras permit fundus imaging and ... operation without any need for eyepieces ... findings. Image recording and display is ... utilizes the ophthalmoscope principle of modern ...

... The ARIS A utomated R ... revolutionary, patented technology which provides rapid and automated ... allows eye care professionals to screen and ... in less time and at ...

Medicine Products:

CoEase ProVisc VISUCAM Digital Camera ARIS Automated Retinal Imaging System